Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells.
Sign Up to like & getrecommendations! Published in 2020 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2020.08.012
Abstract: Triple-negative breast cancer (TNBC), characterized by decreased expression of hormone receptors and human epidermal growth factor type 2 receptor, has poor prognosis and lacks effective therapeutics. Recently, the mTOR inhibitor rapamycin and its analogs have… read more here.
Keywords: rictor; negative breast; breast cancer; rapamycin insensitive ... See more keywords